MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.385
-0.025 (-1.77%)
At close: May 12, 2026, 4:00 PM EDT
1.380
-0.005 (-0.36%)
After-hours: May 12, 2026, 4:10 PM EDT
MediciNova Revenue
In the year 2025, MediciNova had annual revenue of $409.66K. MediciNova had revenue of $151.74K in the quarter ending December 31, 2025.
Revenue (ttm)
$409.66K
Revenue Growth
n/a
P/S Ratio
165.81
Revenue / Employee
$68,276
Employees
6
Market Cap
67.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 409.66K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 4.04M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 6.00M | 5.20M | 648.00% |
| Dec 31, 2012 | 802.58K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 263.88K | -540.19K | -67.18% |
| Dec 31, 2005 | 804.07K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| MindWalk Holdings | 20.70M |
| TScan Therapeutics | 9.14M |
| Immutep | 5.28M |
| Rallybio | 858.00K |
| ImageneBio | 800.00K |
| Impact BioMedical | 32.00K |
MNOV News
- 15 days ago - MediciNova’s peer-reviewed ibudilast study advances clinical translation - TheFly
- 15 days ago - New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - GlobeNewsWire
- 7 weeks ago - Maxim resumes MediciNova at Buy on potential value-driving data events this year - TheFly
- 7 weeks ago - MediciNova resumed with a Buy at Maxim - TheFly
- 2 months ago - MediciNova to Participate at the 38th Annual ROTH Conference - GlobeNewsWire
- 2 months ago - MediciNova initiated with a Buy at H.C. Wainwright - TheFly
- 2 months ago - MediciNova management to meet with Maxim - TheFly
- 3 months ago - MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - GlobeNewsWire